Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L

References

• Callander, N.S. and Roodman, G.D. (2001) "Myeloma bone disease", Seminars in Hematology, 38(3), 276–285.
   PubMed Web of Science ®Google Scholar
• Szczepek, A.J., Seeberger, K., Wizniak, J., Mant, M.J., Belch, A.R., et al. (1998) "A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase- polymerase chain reaction", Blood, 92(8), 2844–2855.
   PubMed Web of Science ®Google Scholar
• Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., et al. (2001) "Connection between B lymphocyte and osteoclast differentiation pathways", Journal of Immunology, 167(5), 2625–2631.
   PubMed Web of Science ®Google Scholar
• Dune, B.G. and Salmon, S.E. (1977) Multiple myeloma, macro-globulinemia and monoclonal gammopathies. In Recent Advances in Haematology, edited by A.V. Hoffbrand, M.C. Brain and J. Hirsh. Pp. 243–261. New York, NY. Churchill Livingstone.
   Google Scholar
• Dune, B.G. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival", Cancer, 36(3), 842–854.
   Google Scholar
• Bull, H., Murray, P.G., Thomas, D., Fraser, A.M. and Nelson, P.N. (2002) "Acid phosphatases", Molecular Pathology, 55(2), 65–72.
   PubMedGoogle Scholar
• Higuchi, Y., Ito, M., Tajima, M., Higuchi, S., Miyamoto, N., Nishio, M., et al. (1999) "Gene expression during osteoclast-like cell formation induced by antifusion regulatory protein-1/CD98/4F2 monoclonal antibodies (MAbs): c-src is selectively induced by anti-FRP-1 MAb", Bone, 25(1), 17–24.
   PubMed Web of Science ®Google Scholar
• Walsh, C.A., Beresford, J.N., Birch, M.A., Boothroyd, B. and Gallagher, J.A. (1991) "Application of reflected light microscopy to identify and quantitate resorption by isolated osteoclasts", Journal of Bone and Mineral Research, 6(7), 661— 671.
   Google Scholar
• James, I.E., Dodds, R.A., Lee-Rykaczewski, E., Eichman, C.F., Connor, J.R., Hart, T.K., et al. (1996) "Purification and character-ization of fully functional human osteoclast precursors", Journal of Bone and Mineral Research, 11(11), 1608–1618.
   PubMed Web of Science ®Google Scholar
• Gregoretti, M.G., Bergui, L., Aragno, M., Cremona, O., Marchisio, P.C. and Caligaris-Cappio, F. (1995) "Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma", Leukemia, 9(8), 1392–1397.
   PubMed Web of Science ®Google Scholar
• Szczepek, A.J., Bergsagel, P.L., Axelsson, L., Brown, C.B., Belch, A.R. and Pilarski, L.M. (1997) "CD34 + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements", Blood, 89(5), 1824 — 1833.
   PubMed Web of Science ®Google Scholar
• Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., et al. (1999) "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node orga-nogenesis", Nature, 397(6717), 315–323.
   PubMed Web of Science ®Google Scholar
• Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T. and Shultz, L.D. (1990) "The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene", Nature, 345(6274), 442–444.
   PubMed Web of Science ®Google Scholar
• Lagasse, E. and Weissman, I.L. (1997) "Enforced expression of Bel-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice", Cell, 89(7), 1021–1031.
   PubMed Web of Science ®Google Scholar
• Kastrinakis, N.G., Gorgoulis, V.G., Foukas, P.G., Dimopoulos, M.A. and Kittas, C. (2000) "Molecular aspects of multiple myeloma", Annals of Oncology, 11(10), 1217–1228.
   PubMed Web of Science ®Google Scholar
• Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon-Mantel, A., Fermand, J.P., et al. (2002) "RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma", British Journal of Haematology, 117(1), 86–92.
   PubMed Web of Science ®Google Scholar
• Hofbauer, L.C., Neubauer, A. and Heufelder, A.E. (2001) "Receptor activator of nuclear factor-kappaB ligand and osteopro-tegerin: potential implications for the pathogenesis and treatment of malignant bone diseases", Cancer, 92(3), 460–470.
   PubMed Web of Science ®Google Scholar
• Shalhoub, V., Elliott, G., Chiu, L., Manoulcian, R., Kelley, M., Hawkins, N., et al. (2000) "Characterization of osteoclast pre-cursors in human blood", British Journal of Haematology, 111(2), 501— 512.
   Google Scholar
• Croucher, PT., Shipman, C.M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., et al. (2001) "Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma", Blood, 98(13), 3534— 3540.
   Google Scholar
• Pilarski, L.M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R.W. and Belch, A.R. (2000) "Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice", Blood, 95(3), 1056–1065.
   PubMed Web of Science ®Google Scholar
• Reiman, T., Seeberger, K., Taylor, B.J., Szczepek, A.J., Hanson, J., Mant, M.J., et al. (2001) "Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switch-ing within the myeloma clone", Blood, 98(9), 2791–2799.
   PubMed Web of Science ®Google Scholar